Omega-3 Plus Low-Dose Aspirin in Smokers With Stage III Periodontitis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age30-50
SponsorAl-Azhar University
About this trial
This randomized double-blind placebo-controlled clinical trial aims to evaluate the clinical and biochemical effects of omega-3 fatty acids combined with low-dose aspirin as an adjunct to scaling and root planing (SRP) in smoker patients with Stage III periodontitis. The study compares test and control groups regarding periodontal clinical parameters and gingival crevicular fluid interleukin-1 beta (IL-1β) levels Or other inflammatory markers that will be determined later at baseline, 3 months, and 6 months following treatment
Eligibility criteria
Qualifiers
- Male or female smokers aged 30 to 50 years.
Diagnosed with Stage III periodontitis according to the 2017 World Workshop classification.
Probing pocket depth (PPD) ≥ 5 mm.
Clinical attachment loss (CAL) ≥ 5 mm.
Disqualifiers
- Systemic diseases affecting periodontal health.
Pregnancy or lactation.
Periodontal treatment within the previous 6 months.
Use of antibiotics or anti-inflammatory drugs within the previous 6 months.
Trial design
Treatments tested in this trial
- Omega-3 Fatty Acids (EPA plus DHA) plus low dose aspirin
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov